company background image
MIRM

Mirum Pharmaceuticals NasdaqGM:MIRM Stock Report

Last Price

US$31.70

Market Cap

US$1.5b

7D

-1.1%

1Y

72.9%

Updated

04 Dec, 2023

Data

Company Financials +

Mirum Pharmaceuticals, Inc.

NasdaqGM:MIRM Stock Report

Mkt Cap: US$1.5b

MIRM Stock Overview

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.

MIRM fundamental analysis
Snowflake Score
Valuation4/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Mirum Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Mirum Pharmaceuticals
Historical stock prices
Current Share PriceUS$31.70
52 Week HighUS$33.39
52 Week LowUS$17.49
Beta1.2
1 Month Change5.67%
3 Month Change14.77%
1 Year Change72.94%
3 Year Change33.47%
5 Year Changen/a
Change since IPO139.97%

Recent News & Updates

Recent updates

What Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) P/S Is Not Telling You

Jun 10
What Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) P/S Is Not Telling You

Industry Analysts Just Made A Captivating Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Revenue Forecasts

Apr 18
Industry Analysts Just Made A Captivating Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Revenue Forecasts

Mirum's liver disease drug Livmarli gets EMA committee nod for approval in EU

Oct 14

Mirum: Great Sales Start For Livmarli Paves The Way For Long-Term Growth

Aug 17

Mirum Pharmaceuticals announces $80M stock offering

Aug 09

Mirum Pharmaceuticals: Post-Approval Execution Looks Excellent

May 27

Is Mirum Pharmaceuticals (NASDAQ:MIRM) In A Good Position To Invest In Growth?

Apr 22
Is Mirum Pharmaceuticals (NASDAQ:MIRM) In A Good Position To Invest In Growth?

Mirum Pharmaceuticals Gets The 'Thumbs Up'

Dec 16

Need To Know: Analysts Just Made A Substantial Cut To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates

Nov 25
Need To Know: Analysts Just Made A Substantial Cut To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates

Mirum And Maralixibat In Pediatric Cholestasis: The Differentiation

Aug 24

Analysts Have Made A Financial Statement On Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Second-Quarter Report

Aug 09
Analysts Have Made A Financial Statement On Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Second-Quarter Report

We're Keeping An Eye On Mirum Pharmaceuticals' (NASDAQ:MIRM) Cash Burn Rate

Jul 28
We're Keeping An Eye On Mirum Pharmaceuticals' (NASDAQ:MIRM) Cash Burn Rate

Mirum Is Undervalued Despite Expected Tough Competition

Jun 01

Mirum gets notice of allowance from United States Patent and Trademark Office

Apr 26

We're Not Very Worried About Mirum Pharmaceuticals' (NASDAQ:MIRM) Cash Burn Rate

Mar 29
We're Not Very Worried About Mirum Pharmaceuticals' (NASDAQ:MIRM) Cash Burn Rate

What Type Of Shareholders Make Up Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Share Registry?

Feb 22
What Type Of Shareholders Make Up Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Share Registry?

Mirum kicks off enrolment in Phase 2b VISTAS study of volixibat

Jan 14

Mirium Pharmaceuticals +4%, provides corporate update

Jan 12

Christopher Peetz Is The President of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) And They Just Picked Up 2.5% More Shares

Dec 30
Christopher Peetz Is The President of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) And They Just Picked Up 2.5% More Shares

Shareholder Returns

MIRMUS BiotechsUS Market
7D-1.1%3.8%0.9%
1Y72.9%-5.8%13.6%

Return vs Industry: MIRM exceeded the US Biotechs industry which returned -7.8% over the past year.

Return vs Market: MIRM exceeded the US Market which returned 11.7% over the past year.

Price Volatility

Is MIRM's price volatile compared to industry and market?
MIRM volatility
MIRM Average Weekly Movement6.7%
Biotechs Industry Average Movement11.4%
Market Average Movement6.1%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.9%

Stable Share Price: MIRM is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: MIRM's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2018249Chris Peetzhttps://www.mirumpharma.com

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company’s lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of primary sclerosing cholangitis and primary biliary cholangitis in adults.

Mirum Pharmaceuticals, Inc. Fundamentals Summary

How do Mirum Pharmaceuticals's earnings and revenue compare to its market cap?
MIRM fundamental statistics
Market CapUS$1.49b
Earnings (TTM)-US$164.19m
Revenue (TTM)US$144.73m

10.2x

P/S Ratio

-9.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MIRM income statement (TTM)
RevenueUS$144.73m
Cost of RevenueUS$26.51m
Gross ProfitUS$118.21m
Other ExpensesUS$282.40m
Earnings-US$164.19m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-3.52
Gross Margin81.68%
Net Profit Margin-113.45%
Debt/Equity Ratio113.7%

How did MIRM perform over the long term?

See historical performance and comparison